Stocks
Allogene Therapeutics (ALLO) EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -179.9 | -250.8 | -169.7 | -335.4 | -300.3 | -269.0 | ||
| Changes by years, y/y, % | -14% | +39% | -32% | +98% | -10% | +7.6% | |||
Allogene Therapeutics. EBITDA US GAAP, bln rub
Allogene Therapeutics. EBITDA US GAAP, changes, %
Allogene Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Allogene Therapeutics (ALLO) EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA, bln rub | ? | -59.4 | -68.5 | -65.9 | -62.8 | -71.8 | -269.0 | |
| Changes by years, y/y, % | -24% | -29% | -33% | -18% | +21% | |||
| Changes by quarters, q/q, % | -23% | +15% | -4% | -5% | +14% | |||
